

National Cancer Institute
Institutional Review Board

AGENDA

February 11, 2013

1:00 – 5:00 pm

CRC/3-1608

- 1. Review of Draft Minutes, January 28, 2013**
- 2. Announcements**
- 3. Old Business**
- 4. New Business**
 - 07C0195 (Steven Pavletic, PI) Safety Review
- 5. Adverse Events/Unanticipated Problems/Violations**
- 6. Other Expedited Actions**
- 7. Continuing Reviews/Terminations**
- 8. Amendment** 10C0025E, "Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia" - Robert Kreitman, PI
- 9. Amendment** 09C0005, "Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease"—Robert Kreitman, PI
- 10. Amendment** 08C0200H, "A Pilot Study of 18F fluorothymidine (FLT) PET/CT in Lymphoma" - Karen Ann Kurdziel, MD, PI
- 11. Amendment** 11C0160F, "A Pilot Study of Pentostatin plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients with Mesothelioma" - Raffit Hassan, PI
- 12. Amendment** 12C0047D, "A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV" - Robert Yarchoan, PI
- 13. Initial Review** P131209, "Phase II Study in Patients with Metastatic Ocular Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes with or without High Dose Aldesleukin" - Udai Kammula, PI
- 14. Initial Review** P121195, "Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies"-- Deborah Citrin, PI